American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(5), P. 424 - 437
Published: May 1, 2025
Posttraumatic
stress
disorder
(PTSD)
symptoms
are
part
of
the
normal
response
to
trauma.
Most
trauma
survivors
will
recover
over
time
without
intervention,
but
a
significant
minority
develop
chronic
PTSD,
which
is
unlikely
remit
intervention.
Currently,
only
two
medications,
sertraline
and
paroxetine,
approved
by
U.S.
Food
Drug
Administration
treat
combination
brexpiprazole
MDMA-assisted
therapy
have
FDA
applications
pending.
These
pharmacotherapy
psychotherapy,
not
recommended
as
first-line
treatments
in
any
published
PTSD
treatment
guidelines.
The
interventions
trauma-focused
psychotherapies;
Department
Veterans
Affairs/Department
Defense
guideline
recommends
prolonged
exposure
(PE),
cognitive
processing
(CPT),
eye
movement
desensitization
reprocessing,
American
Psychological
Association
PE,
CPT,
therapy,
cognitive-behavioral
therapy.
Although
clinical
trials
psychedelic-assisted
psychotherapy
incorporated
evidence-based
psychotherapies,
they
achieved
greater
rates
than
other
treatment,
there
some
enthusiasm
about
combining
psychedelic
medications
with
psychotherapies.
state-of-the-art
psychotherapies
briefly
reviewed
here,
including
their
effects
on
neurobiological
measures.
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(1), P. 47 - 53
Published: Jan. 1, 2025
The
last
few
years
have
seen
exponential
growth
in
interest,
investment,
advocacy,
and
research
into
psychedelics
as
therapeutics.
This
reflects
an
optimism
about
the
potential
promise
of
As
with
all
therapeutic
interventions,
is
needed
not
only
their
benefits
but
also
risks.
Indeed,
when
substances
are
scrutinized
over
time,
especially
broad
populations
psychiatric
medical
comorbidities
typically
excluded
from
clinical
trials,
applied
less
well-regulated
or
controlled
settings,
a
greater
understanding
cautions
emerges.
Here,
we
review
literature
on
known
harms,
including
enduring
perceptual
disturbances;
triggering
enhancing
risk
for
onset
mania
psychosis;
overuse,
misuse,
dependence;
challenging
experiences
"bad
trips";
risks
associated
increased
neuroplastic
potential;
acute
cumulative
cardiovascular
effects.
Each
these
issues
addressed
this
review,
along
call
continued
research,
recommendations
further
monitoring.
ACS Pharmacology & Translational Science,
Journal Year:
2025,
Volume and Issue:
8(3), P. 903 - 906
Published: Feb. 10, 2025
Autism
Spectrum
Disorders
(ASD)
are
complex
neurodevelopmental
conditions
characterized
by
deficits
in
social
interaction,
communication,
and
repetitive
behaviors.
This
viewpoint
explores
the
potential
mechanisms
through
which
psychedelics
such
as
lysergic
acid
diethylamide
(LSD),
psilocybin,
3,4-methylenedioxymethamphetamine
(MDMA)
may
positively
influence
pro-social
behaviors,
focusing
on
their
implications
for
individuals
with
ASD.
Journal of Psychoactive Drugs,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 17
Published: March 31, 2025
Psychedelic-assisted
therapy
is
gaining
recognition
for
its
potential
to
enhance
human
functioning.
While
most
research
has
focused
on
psychedelic'
therapeutic
use
mental
illness,
this
review
applies
the
PERMA
Theory
of
Well-Being
systematically
examine
their
role
in
enhancing
well-being
healthy
individuals.
The
final
search
five
academic
databases
was
conducted
February
4,
2024,
including
studies
published
from
1994.
After
applying
inclusion
criteria
(controlled
or
naturalistic
experimental
design
with
an
outcome
measurement
at
least
7
days
post-consumption),
19
were
included.
Encompassing
949
participants,
two
involved
5-methoxy-N,N-dimethyltryptamine
(5-MeO-DMT),
seven
ayahuasca,
lysergic
acid
diethylamide
(LSD),
and
eight
psilocybin.
Results
consistently
indicate
psychedelic
consumption
related
enduring
enhancements
PERMA's
elements
well-being,
positive
emotions,
engagement,
relationships,
meaning,
accomplishment.
discussion
adverse
effects
frequently
absent,
no
serious
reported
six
studies.
Future
should
address
limitations
included
by
conducting
larger-scale,
longitudinal
randomized
controlled
trials
that
incorporate
a
comprehensive
assessment
well-being.
Nevertheless,
findings
systematic
call
paradigm
shift,
moving
beyond
disease-focused
lens
recognizing
psychedelics'
capacity
individuals,
ultimately
fostering
flourishing.
American Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
182(5), P. 424 - 437
Published: May 1, 2025
Posttraumatic
stress
disorder
(PTSD)
symptoms
are
part
of
the
normal
response
to
trauma.
Most
trauma
survivors
will
recover
over
time
without
intervention,
but
a
significant
minority
develop
chronic
PTSD,
which
is
unlikely
remit
intervention.
Currently,
only
two
medications,
sertraline
and
paroxetine,
approved
by
U.S.
Food
Drug
Administration
treat
combination
brexpiprazole
MDMA-assisted
therapy
have
FDA
applications
pending.
These
pharmacotherapy
psychotherapy,
not
recommended
as
first-line
treatments
in
any
published
PTSD
treatment
guidelines.
The
interventions
trauma-focused
psychotherapies;
Department
Veterans
Affairs/Department
Defense
guideline
recommends
prolonged
exposure
(PE),
cognitive
processing
(CPT),
eye
movement
desensitization
reprocessing,
American
Psychological
Association
PE,
CPT,
therapy,
cognitive-behavioral
therapy.
Although
clinical
trials
psychedelic-assisted
psychotherapy
incorporated
evidence-based
psychotherapies,
they
achieved
greater
rates
than
other
treatment,
there
some
enthusiasm
about
combining
psychedelic
medications
with
psychotherapies.
state-of-the-art
psychotherapies
briefly
reviewed
here,
including
their
effects
on
neurobiological
measures.
